Company
Novo Nordisk
Novo Nordisk A/S
Public (NYSE:NVO) · Bagsværd, Denmark · Last verified Aug 15, 2024
Danish metabolic specialist; markets semaglutide and develops next-generation combinations.
Company profile
- Legal name
- Novo Nordisk A/S
- Status
- public
- Ticker
- NYSE:NVO
- Headquarters
- Bagsværd, Denmark
- Website
- www.novonordisk.com
Active assets
| Asset | Stage | Indications |
|---|---|---|
| Semaglutide | Approved | — |
| Cagrisema | Phase 3 | — |
| Oral semaglutide | Approved | — |
Trial roll-up
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT04184622 | Phase 3 | A Research Study to Look at How Semaglutide Works Compared to Placebo in People With Overweight or Obesity | Completed |
| NCT05929066 | Phase 3 | A Study to Evaluate the Effect of CagriSema on Body Weight in Adults Living With Overweight or Obesity | Active, not recruiting |
Deals
View all →| Parties | Type | Headline value | Announced |
|---|---|---|---|
| Novo Nordisk A/S / Emisphere Technologies Inc. | licensing | Up to $105 million (contingent) | Nov 5, 2007 |